Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,028 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population.
Maglalang PD, Sinha J, Zimmerman K, McCann S, Edginton A, Hornik CP, Hornik CD, Muller WJ, Al-Uzri A, Meyer M, Chen JY, Anand R, Perrin EM, Gonzalez D; Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Maglalang PD, et al. Clin Pharmacokinet. 2024 May 30. doi: 10.1007/s40262-024-01367-2. Online ahead of print. Clin Pharmacokinet. 2024. PMID: 38814425
Collagen-derived dipeptide prolyl-hydroxyproline cooperates with Foxg1 to activate the PGC-1α promoter and induce brown adipocyte-like phenotype in rosiglitazone-treated C3H10T1/2 cells.
Nomura K, Kimira Y, Kobayashi R, Shiobara Y, Osawa Y, Kataoka-Matsushita A, Shimizu J, Wada M, Mano H. Nomura K, et al. Among authors: shimizu j. Front Nutr. 2024 May 15;11:1375532. doi: 10.3389/fnut.2024.1375532. eCollection 2024. Front Nutr. 2024. PMID: 38812940 Free PMC article.
Correction to: RFC1‑related disorder presenting recurrent syncope.
Tsuboyama Y, Takahashi A, Furukawa S, Almansour A, Hamada M, Kubota A, Shimizu J, Kinoshita M, Fujimoto C, Mitsui J, Matsukawa T, Naruse H, Ishiura H, Tsuji S, Toda T. Tsuboyama Y, et al. Among authors: shimizu j. J Neurol. 2024 May 27. doi: 10.1007/s00415-024-12394-1. Online ahead of print. J Neurol. 2024. PMID: 38802625 No abstract available.
ASO Visual Abstract: Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).
Yamada D, Kobayashi S, Takahashi H, Iwagami Y, Akita H, Asukai K, Shimizu J, Yamada T, Tanemura M, Yokoyama S, Tsujie M, Asaoka T, Takeda Y, Morimoto O, Tomokuni A, Doki Y, Eguchi H. Yamada D, et al. Among authors: shimizu j. Ann Surg Oncol. 2024 May 25. doi: 10.1245/s10434-024-15479-3. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38796587 No abstract available.
ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma (R/BR-PDAC)?
Yamada D, Kobayashi S, Takahashi H, Iwagami Y, Akita H, Asukai K, Shimizu J, Yamada T, Tanemura M, Yokoyama S, Tsujie M, Asaoka T, Takeda Y, Morimoto O, Tomokuni A, Doki Y, Eguchi H. Yamada D, et al. Among authors: shimizu j. Ann Surg Oncol. 2024 May 9. doi: 10.1245/s10434-024-15244-6. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38722422 No abstract available.
1,028 results